{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:19:52Z","timestamp":1791073192164,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"12","content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.tim.2013.09.008","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T05:46:31Z","timestamp":1384407991000},"page":"625-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Treatment as prevention and cure towards global eradication of hepatitis C virus"],"prefix":"10.1016","volume":"21","author":[{"given":"Liesl M.","family":"Hagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Root","family":"Wolpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tim.2013.09.008_bib0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/cir306","article-title":"All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population","volume":"53","author":"El-Kamary","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.tim.2013.09.008_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2011.01499.x","article-title":"The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference","volume":"18","author":"Hatzakis","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tim.2013.09.008_bib0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"Rein","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2893.2007.00946.x","article-title":"Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5","volume":"15","author":"Antaki","year":"2008","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tim.2013.09.008_bib0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2011.09.008","article-title":"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C","volume":"56","author":"Asselah","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tim.2013.09.008_bib0030","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2010.11.016","article-title":"Management of hepatitis C virus genotype 4: recommendations of an international expert panel","volume":"54","author":"Khattab","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tim.2013.09.008_bib0035","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2013.09.008_bib0040","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0045","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2893.2009.01226.x","article-title":"Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2\/3 vs 6","volume":"17","author":"Nguyen","year":"2010","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tim.2013.09.008_bib0050","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2893.2010.01373.x","article-title":"Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a","volume":"18","author":"Zhou","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tim.2013.09.008_bib0055","first-page":"1","article-title":"NIH Consensus Statement on Management of Hepatitis C","volume":"19","author":"National Institutes of Health","year":"2002","journal-title":"NIH Consens. State Sci. Statements"},{"key":"10.1016\/j.tim.2013.09.008_bib0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0065","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","article-title":"A Phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1","volume":"59","author":"Lawitz","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tim.2013.09.008_bib0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jgh.12028","article-title":"Current prospects for interferon-free treatment of hepatitis C in 2012","volume":"28","author":"Stedman","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tim.2013.09.008_bib0085","series-title":"Smallpox and its Eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.tim.2013.09.008_bib0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1748-720X.2002.tb00384.x","article-title":"Public health ethics: mapping the terrain","volume":"30","author":"Childress","year":"2002","journal-title":"J. Law Med. Ethics"},{"issue":"Suppl. 1","key":"10.1016\/j.tim.2013.09.008_bib0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/liv.12063","article-title":"Best strategies for global HCV eradication","volume":"33","author":"Hagan","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.tim.2013.09.008_bib0100","series-title":"HIV DART: Frontiers in Drug Development for Antiretroviral Therapies","article-title":"Treatment as prevention: moving from HIV to HCV","author":"Montaner","year":"2012"},{"key":"10.1016\/j.tim.2013.09.008_bib0105","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0140-6736(06)69162-9","article-title":"The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic","volume":"368","author":"Montaner","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2013.09.008_bib0110","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/QAD.0b013e3283394f5b","article-title":"Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to-child HIV transmission","volume":"24","author":"Kuhn","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.tim.2013.09.008_bib0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/13543776.2012.673589","article-title":"Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities","volume":"22","author":"Roohvand","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tim.2013.09.008_bib0120","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2013.09.008_bib0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2012.07.006","article-title":"Therapeutic vaccination against chronic hepatitis C virus infection","volume":"96","author":"Ip","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2013.09.008_bib0130","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1586\/erv.12.52","article-title":"Challenges for HCV vaccine development in HIV\u2013HCV coinfection","volume":"11","author":"Lambotin","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.tim.2013.09.008_bib0135","series-title":"Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of hepatitis B and C","author":"Institute of Medicine","year":"2010"},{"key":"10.1016\/j.tim.2013.09.008_bib0140","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1471-6712.2008.00668.x","article-title":"Increasing public awareness about hepatitis C: development and validation of the brief hepatitis C knowledge scale","volume":"23","author":"Balfour","year":"2009","journal-title":"Scand. J. Caring Sci."},{"key":"10.1016\/j.tim.2013.09.008_bib0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0399-8320(07)89416-4","article-title":"Hepatitis C awareness among adolescents in the Alpes-Maritimes area of France","volume":"31","author":"Gardella","year":"2007","journal-title":"Gastroenterol. Clin. Biol."},{"key":"10.1016\/j.tim.2013.09.008_bib0150","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: an estimate of true prevalence","volume":"31","author":"Chak","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.tim.2013.09.008_bib0155","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12111","article-title":"All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses","author":"Hagan","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tim.2013.09.008_bib0160","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1302973","article-title":"Hepatitis C in the United States","volume":"368","author":"Holmberg","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2006.07.9111","article-title":"Cost of cancer care: the patient perspective","volume":"25","author":"Kim","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tim.2013.09.008_bib0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.2006.09.6081","article-title":"Cost of cancer care: issues and implications","volume":"25","author":"Meropol","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tim.2013.09.008_bib0175","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep.25556","article-title":"Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001\u20132008","volume":"55","author":"Denniston","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.tim.2013.09.008_bib0180","first-page":"30","article-title":"HIV\/HCV coinfection: a new era of treatment","volume":"23","author":"Highleyman","year":"2011","journal-title":"BETA"},{"key":"10.1016\/j.tim.2013.09.008_bib0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dld.2010.05.006","article-title":"Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States","volume":"43","author":"Rein","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.tim.2013.09.008_bib0195","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2105\/AJPH.90.10.1562","article-title":"Estimating future hepatitis C morbidity, mortality, and costs in the United States","volume":"90","author":"Wong","year":"2000","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.tim.2013.09.008_bib0200","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-127-10-199711150-00001","article-title":"Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C","volume":"127","author":"Bennett","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0205","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/cid\/cis011","article-title":"Cost-effectiveness and population outcomes of general population screening for hepatitis C","volume":"54","author":"Coffin","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2013.09.008_bib0210","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/lt.22129","article-title":"Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma","volume":"16","author":"Naugler","year":"2010","journal-title":"Liver Transpl."},{"key":"10.1016\/j.tim.2013.09.008_bib0215","unstructured":"Berry, J. (2013) Don\u2019t break the bank: assistance programs can help pay for meds. Positively Aware March\u2013April 2013, 70\u201373"},{"key":"10.1016\/j.tim.2013.09.008_bib0220","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/apc.1999.13.577","article-title":"Compulsory licensing and the AIDS epidemic in South Africa","volume":"13","author":"Saslow","year":"1999","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.tim.2013.09.008_bib0225","first-page":"90","article-title":"The Brazilian experiment: HIV drugs for all","volume":"36","author":"Flaer","year":"2009","journal-title":"J. Health Care Finance"},{"key":"10.1016\/j.tim.2013.09.008_bib0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","article-title":"Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers","volume":"96","author":"Carlson","year":"2010","journal-title":"Health Policy"},{"key":"10.1016\/j.tim.2013.09.008_bib0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.26304","article-title":"The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States","volume":"58","author":"McEwan","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.tim.2013.09.008_bib0240","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0245","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2013.09.008_bib0250","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","article-title":"The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt","volume":"355","author":"Frank","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2013.09.008_bib0255","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","article-title":"HCV burden of infection in Egypt: results from a nationwide survey","volume":"19","author":"Guerra","year":"2012","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tim.2013.09.008_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350501000118","article-title":"Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes","volume":"10","author":"Hnatyszyn","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.tim.2013.09.008_bib0265","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/MPG.0b013e318258328d","article-title":"NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents","volume":"54","author":"Mack","year":"2012","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.tim.2013.09.008_bib0270","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/jmv.21480","article-title":"Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages","volume":"81","author":"Shebl","year":"2009","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.tim.2013.09.008_bib0275","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.trstmh.2005.05.021","article-title":"Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women","volume":"100","author":"Stoszek","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.tim.2013.09.008_bib0280","doi-asserted-by":"crossref","first-page":"827","DOI":"10.7196\/SAMJ.4045","article-title":"Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa","volume":"100","author":"Fitzgerald","year":"2010","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.tim.2013.09.008_bib0285","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/QAD.0b013e3282f9b67a","article-title":"Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000\u20132006","volume":"22","author":"Townsend","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.tim.2013.09.008_bib0290","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/jvh.12080","article-title":"Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C","volume":"20","author":"Younossi","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tim.2013.09.008_bib0295","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.drugpo.2007.01.009","article-title":"Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection","volume":"18","author":"Grebely","year":"2007","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.tim.2013.09.008_bib0300","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2013.09.008_bib0305","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2013.09.008_bib0310","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.24754","article-title":"Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection","volume":"55","author":"Grebely","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.tim.2013.09.008_bib0315","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2013.03.008","article-title":"Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C","volume":"59","author":"Marco","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tim.2013.09.008_bib0320","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/cid\/cit377","article-title":"Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements","volume":"57","author":"Grebely","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2013.09.008_bib0325","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1097\/QAD.0b013e32836381cc","article-title":"HCV reinfection incidence and treatment outcome among HIV-positive MSM","volume":"27","author":"Martin","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.tim.2013.09.008_bib0330","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","article-title":"Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility","volume":"54","author":"Martin","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tim.2013.09.008_bib0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.24656","article-title":"Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations","volume":"55","author":"Martin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.tim.2013.09.008_bib0340","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jama.2012.374","article-title":"Screening for HCV infection in jails","volume":"307","author":"Spaulding","year":"2012","journal-title":"J. Am. Med. Assoc."}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X13001856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X13001856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T13:36:54Z","timestamp":1688650614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X13001856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0966842X13001856"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2013.09.008","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment as prevention and cure towards global eradication of hepatitis C virus","name":"articletitle","label":"Article Title"},{"value":"Trends in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tim.2013.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}